Lower odds of prevalent vertebral fractures with b/tsDMARD use among rheumatoid arthritis patients in clinical remission: a retrospective observational study

By
Yu Yamashita
Kazuhiro Maeda
Asami Zenitani
Mitsuru Saito
May 13, 2026
0 min

Clinical Rheumatology

Overview

Revise to clarify the relationship between b/tsDMARD use and serum pentosidine levels.

Background

Rheumatoid arthritis (RA) is associated with systemic bone loss and an increased risk of fragility fractures, particularly in the vertebrae. The chronic inflammation characteristic of RA contributes to bone quality deterioration, leading to fractures even in patients with normal bone mineral density. Understanding the impact of b/tsDMARDs on fracture risk in RA patients is crucial for improving patient outcomes.

Data Highlights

No numerical data available in the source material.

Key Findings

Patients with RA in clinical remission using b/tsDMARDs had a lower prevalence of vertebral fractures.
Serum pentosidine levels, indicative of bone quality, were significantly lower in patients treated with b/tsDMARDs.
Residual inflammatory activity, assessed by DAS28 scores, was correlated with serum pentosidine levels.
The study included 76 patients with RA, all in clinical remission, to minimize confounding factors.
Vertebral fracture assessment was performed using lateral thoracolumbar spine radiographs in 51 patients.

Clinical Implications

The findings suggest that b/tsDMARDs may play a protective role against vertebral fractures in RA patients in remission. Clinicians should consider the use of these therapies not only for managing RA symptoms but also for preserving bone health and reducing fracture risk.

Conclusion

The study highlights the potential benefits of b/tsDMARDs in reducing vertebral fracture prevalence among RA patients in clinical remission, emphasizing the importance of monitoring bone health in this population.